Royalty Pharma has seen several significant developments suggesting a positive direction for the company. The company's market position continues to strengthen, with KLP Kapitalforvaltning, Belpointe Asset Management, and Robeco Institutional Asset Management among those increasing their holding in their stocks. The company has also seen promising performance. They reported a
20% portfolio growth, posting $727 million in Q2 receipts. Continued growth seems likely with the institution of a bold $4 billion in new deals and funding moves. The company is also planning to announce its Q3 2025 financial results soon. Several well-reputed financial institutions like
Goldman Sachs and Weiss Ratings have given Royalty Pharma stocks a 'buy' rating. Royalty Pharma continues its expansion with notable acquisitions, like the $950 million cancer royalty deal with
Amgen and $300M commitment to Zenas’s Obexelimab program. These optimistic signals are reflected in
Royalty Pharma's stocks hitting 52-week high multiple times.
Royalty Pharma Stocks News Analytics from Tue, 24 Dec 2024 08:00:00 GMT to Sat, 11 Oct 2025 07:55:39 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor 3
